Taysha Gene Therapies (TSHA) Receives a Rating Update from a Top Analyst
Taysha Gene Therapies (TSHA) has received a Strong Buy consensus rating from analysts, with an average price target of $10.27, indicating a potential upside of 140.52%. Analyst Lee, who covers the Healthcare sector, has a notable average return of 31.4% and a success rate of 57.47% on stock recommendations. Citizens JMP also maintains a Buy rating with a price target of $8.00.
Lee covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Praxis Precision Medicines, and Corcept Therapeutics. According to TipRanks, Lee has an average return of 31.4% and a 57.47% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Taysha Gene Therapies with a $10.27 average price target, implying a 140.52% upside from current levels. In a report released today, Citizens JMP also maintained a Buy rating on the stock with a $8.00 price target.
